Physician profile
Patrick J Mcmahon
NPI 1245423854
$132,722.90
in general payments reported to CMS, 2019-2025
31 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.13 · 2021: $104 · 2022: $5,745 · 2023: $28K · 2024: $40K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Travel and Lodging: $8,354 · Food and Beverage: $5,772 · Consulting Fee: $2,600 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,030.50 |
| Travel and Lodging | $8,353.63 |
| Food and Beverage | $5,771.62 |
| Consulting Fee | $2,600.00 |
| Education | $103.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $82,142.22 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $36,871.12 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $5,681.62 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $2,787.65 | 2023-2024 | Vtama |
| Pierre Fabre Pharmaceuticals, INC. | $2,634.25 | 2023-2024 | Hemangeol |
| Leo Pharma INC. | $356.72 | 2022-2025 | Adbry |
| Abbvie INC. | $250.74 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $231.66 | 2023-2025 | Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $167.15 | 2023-2024 | Sotyktu |
| Pfizer INC. | $147.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $147.34 | 2023-2025 | |
| Janssen Biotech, INC. | $142.61 | 2022-2025 | Tremfya |
| Amgen INC. | $140.13 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $139.79 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $135.26 | 2022-2025 | Taltz, Ebglyss, Olumiant |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $124.19 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $111.38 | 2024-2025 | Zoryve |
| Organon LLC | $96.05 | 2024-2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $87.97 | 2024-2025 | Nemluvio, Aklief |
| Nobelpharma America, LLC | $59.52 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $44.21 | 2023-2024 | Idacio |
| Krystal Biotech INC | $36.92 | 2024 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.91 | 2022-2024 | Cabtreo |
| Sandoz INC. | $29.21 | 2023 | Hyrimoz |
| Journey Medical Corporation | $27.09 | 2023 | |
| Springworks Therapeutics, INC. | $24.36 | 2025 | Gomekli |
| Helsinn Therapeutics (U.S.), INC. | $18.39 | 2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $13.39 | 2024 | Poteligeo |
| Braintree Laboratories, INC. | $13.32 | 2022 | |
| Redhill Biopharma INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.